CTOs on the Move

Apeel Sciences

www.Apeel.com

 
Apeel Sciences creates products from natural plant extracts that allow growers to reduce reliance on pesticides, increase produce quality, and provide superior shelf life without refrigeration.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.Apeel.com
  • 819 Reddick Street
    Santa Barbara, CA USA 93103
  • Phone: 877.926.5184

Executives

Name Title Contact Details
Susan McCain
Vice President, Associate General Counsel, Intellectual Property and Risk Profile
Stephen Kaun
Senior Director, Technology Profile

Funding

Apeel Sciences raised $33M on 12/13/2016
Apeel Sciences raised $70M on 07/31/2018
Apeel Sciences raised $30M on 10/27/2020

Similar Companies

Lybradyn Inc

Lybradyn Inc is a Oak Brook, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Provident Research

We specialize in recruiting clinical research talent and understand the hiring objectives of our Medical Device, Biotechnology, and Pharmaceutical clients.

Sonoma Biotherapeutics

Sonoma Biotherapeutics is inventing the future of living therapies for autoimmune disease — safe, effective treatments as unique as each individual patient. Regulatory T cell therapies that harness a patient`s own immune cells, powerful next generation gene editing techniques and advanced manufacturing and quality assurance processes. Sonoma`s mission is to create a best-in-class regulatory T cell therapy that delivers long-lasting, highly efficacious treatments leading to cures across a spectrum of autoimmune and degenerative diseases.

Lumos Diagnostics

Lumos Diagnostics delivers custom diagnostic solutions by combining deep market insight with existing platform technologies, assay development capability and regulated manufacturing experience.

Cerulean

The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Our first platform-generated candidate, CRLX101, is in multiple clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated candidate, CRLX301, is in a Phase 1/2a clinical trial.